Myo-inositol supplementation in women of reproductive age with subclinical hypothyroidism and obesity on the background of vitamin D deficiency

Main Article Content

N.V. Pasyechko
V.M. Kulchinska
S.V. Kadubets


Background. In recent years, thyroid diseases occupy the top places in the structure of the endocrine pathology. There exists a tight functional relationship between the thyroid and reproductive systems, which leads to a high probability of the development of combined disorders in one of these links of homeostasis. The problem of reproductive health disorders is of particular concern around the world and is relevant to the study of the impact of thyroid diseases on both fertility and pregnancy, especially in conditions of comorbidity. The purpose of the study was to investigate the effect of myo-inositol on the reproductive function of women with subclinical hypothyroidism on the background of autoimmune thyroiditis and obesity. Materials and methods. The study included 98 patients aged 18–40 years with subclinical hypothyroidism, overweight, or obesity on the background of autoimmune thyroiditis. They were randomly subdivided into two groups. Patients of the first group (n = 49) before the basic treatment received myo-inositol at a dose of 2000 mg/day and cholecalciferol at a dose of 2000 IU/day. Patients of the second group (n = 49) before the basic treatment received only cholecalciferol at a dose of 2000 IU/day. Results. Vitamin D deficiency was observed in 90.81 % of women with subclinical hypothyroidism, and vitamin D insufficiency in 9.19 %. A negative correlation was found between the level of 25(OH)D and the level of TPO-Ab (r = –0.189; p < 0.05). There was a weak negative correlation between the level of 25(OH)D and the level of the HOMA-IR (r = –0.168; p < 0.05). The administration of myo-inositol together with vitamin D led to a significant increase in the content of 25(OH)D, as well as to a decrease in the titer of TPO-Ab. Conclusions. The positive effect of myo-inositol drugs together with vitamin D on the functional state of the thyroid gland, on the level of TPO-Ab and HOMA-IR in women of reproductive age with subclinical hypothyroidism and obesity has been established.

Article Details

How to Cite
Pasyechko, N., V. Kulchinska, and S. Kadubets. “Myo-Inositol Supplementation in Women of Reproductive Age With Subclinical Hypothyroidism and Obesity on the Background of Vitamin D Deficiency”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 5, Oct. 2021, pp. 443-7, doi:10.22141/2224-0721.17.5.2021.241525.
Original Researches


Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018 May;14(5):301-316. doi:10.1038/nrendo.2018.18.

Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014 Mar;99(3):923-931. doi:10.1210/jc.2013-2409.

Tkachenko VI, Maksymets YaA, Vydyborets NV, Kovalenko OF. Analysis of the prevalence of thyroid pathology and morbidity in the middle of the population of Kyiv region and Ukraine for 2007-2017. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(3):279-284. doi:10.22141/2224-0721.14.3.2018.136426. (in Ukrainian).

Tronko M, Brenner AV, Bogdanova T, et al. Thyroid neoplasia risk is increased nearly 30 years after the Chernobyl accident. Int J Cancer. 2017 Oct 15;141(8):1585-1588. doi:10.1002/ijc.30857.

Yalamanchi S, Cooper DS. Thyroid disorders in pregnancy. Curr Opin Obstet Gynecol. 2015 Dec;27(6):406-415. doi:10.1097/GCO.0000000000000226.

Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019 Jul 9;322(2):153-160. doi:10.1001/jama.2019.9052.

Dong AC, Stagnaro-Green A. Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy: A Systematic Review and Meta-Analysis. Thyroid. 2019 Feb;29(2):278-289. doi:10.1089/thy.2018.0475.

Ahmad S, Geraci SA, Koch CA. Thyroid disease in pregnancy: Women's Health Series. South Med J. 2013 Sep;106(9):532-538. doi:10.1097/SMJ.0b013e3182a66610.

Benvenga S, Antonelli A. Inositol(s) in thyroid function, growth and autoimmunity. Rev Endocr Metab Disord. 2016 Dec;17(4):471-484. doi:10.1007/s11154-016-9370-3.

Chhetri DR. Myo-inositol and its derivatives: their emerging role in the treatment of human diseases. Front Pharmacol. 2019 Oct 11;10:1172. doi:10.3389/fphar.2019.01172.

Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811-1827. doi:10.1016/j.biochi.2013.05.011.

Ferrari SM, Elia G, Ragusa F, et al. The protective effect of myo-inositol on human thyrocytes. Rev Endocr Metab Disord. 2018 Dec;19(4):355-362. doi:10.1007/s11154-018-9476-x.

Reeh K, Summers PA, Gould IR, Woscholski R, Vilar R. Design, synthesis and evaluation of a tripodal receptor for phosphatidylinositol phosphates. Sci Rep. 2020 Oct 28;10(1):18450. doi:10.1038/s41598-020-75484-w.

Song F, Zhang J, Zhao Y, Chen W, Li L, Xi Z. Synthesis and antitumor activity of inositol phosphotriester analogues. Org Biomol Chem. 2012 May 14;10(18):3642-3654. doi:10.1039/c2ob00031h.

Aiba T, Sato M, Umegaki D, et al. Regioselective phosphorylation of myo-inositol with BINOL-derived phosphoramidites and its application for protozoan lysophosphatidylinositol. Org Biomol Chem. 2016 Jul 12;14(28):6672-6675. doi:10.1039/c6ob01062h.

Frej AD, Clark J, Le Roy CI, et al. The Inositol-3-Phosphate Synthase Biosynthetic Enzyme Has Distinct Catalytic and Metabolic Roles. Mol Cell Biol. 2016 May 2;36(10):1464-1479. doi:10.1128/MCB.00039-16.

Nordio M, Pajalich R. Combined treatment with Myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. J Thyroid Res. 2013;2013:424163. doi:10.1155/2013/424163.

Morgante G, Musacchio MC, Orvieto R, Massaro MG, De Leo V. Alterations in thyroid function among the different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2013 Nov;29(11):967-969. doi:10.3109/09513590.2013.829445.

Nordio M, Basciani S. Treatment with Myo-Inositol and Selenium Ensures Euthyroidism in Patients with Autoimmune Thyroiditis. Int J Endocrinol. 2017;2017:2549491. doi:10.1155/2017/2549491.

Porcaro G, Angelozzi P. Myo-inositol and selenium prevent subclinical hypothyroidism during pregnancy: an observational study. IJMDAT. 2018;1(2):e164.

Fallahi P, Ferrari SM, Elia G, et al. Myo-inositol in autoimmune thyroiditis, and hypothyroidism. Rev Endocr Metab Disord. 2018 Dec;19(4):349-354. doi:10.1007/s11154-018-9477-9.

Deja S, Dawiskiba T, Balcerzak W, et al. Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions. PLoS One. 2013 Dec 23;8(12):e84637. doi:10.1371/journal.pone.0084637.

Nordio M, Basciani S. Evaluation of thyroid nodule characteristics in subclinical hypothyroid patients under a myo-inositol plus selenium treatment. Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2153-2159. doi:10.26355/eurrev_201804_14749.

Benvenga S, Nordio M, Laganà AS, Unfer V. The role of inositol in thyroid physiology and in subclinical hypothyroidism management. Front Endocrinol (Lausanne). 2021 May 10;12:662582. doi:10.3389/fendo.2021.662582.

Pankiv IV, Pashkovska N, Koval G, et al. Efficacy of a combined administration of myo-inositol and vitamin D in patients with autoimmune thyroiditis. Endocrine Abstracts. 2021;73:PEP10.4. doi:10.1530/endoabs.73.PEP10.4.

Most read articles by the same author(s)